Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akanda Corp. stock logo
AKAN
Akanda
$5.31
-16.9%		$13.63
$2.30
▼
$209.02
$3.46M14.06340,101 shs88,856 shs
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$0.66
-13.1%		$1.53
$0.66
▼
$6.25
$3.62M1.89277,870 shs224,164 shs
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
$0.62
+3.7%		$0.58
$0.41
▼
$1.75
$3.95M0.75953,697 shs140,432 shs
PainReform Ltd. stock logo
PRFX
PainReform
$1.00
-2.9%		$1.46
$0.97
▼
$17.95
$890K1.05175,442 shs114,540 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akanda Corp. stock logo
AKAN
Akanda
+10.55%-20.82%-53.39%-86.95%-92.27%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
+10.45%-5.70%-47.29%-66.03%-72.21%
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
+7.02%+8.32%+7.68%+5.09%-64.56%
PainReform Ltd. stock logo
PRFX
PainReform
+3.94%-10.43%-25.36%-46.63%-85.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akanda Corp. stock logo
AKAN
Akanda
$5.31
-16.9%		$13.63
$2.30
▼
$209.02
$3.46M14.06340,101 shs88,856 shs
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$0.66
-13.1%		$1.53
$0.66
▼
$6.25
$3.62M1.89277,870 shs224,164 shs
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
$0.62
+3.7%		$0.58
$0.41
▼
$1.75
$3.95M0.75953,697 shs140,432 shs
PainReform Ltd. stock logo
PRFX
PainReform
$1.00
-2.9%		$1.46
$0.97
▼
$17.95
$890K1.05175,442 shs114,540 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akanda Corp. stock logo
AKAN
Akanda
+10.55%-20.82%-53.39%-86.95%-92.27%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
+10.45%-5.70%-47.29%-66.03%-72.21%
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
+7.02%+8.32%+7.68%+5.09%-64.56%
PainReform Ltd. stock logo
PRFX
PainReform
+3.94%-10.43%-25.36%-46.63%-85.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akanda Corp. stock logo
AKAN
Akanda
1.00
SellN/AN/A
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
1.50
ReduceN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
1.00
SellN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest PRFX, CELZ, AKAN, and GLMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
PainReform Ltd. stock logo
PRFX
PainReform
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
5/22/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
5/18/2026
Akanda Corp. stock logo
AKAN
Akanda
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
5/1/2026
Akanda Corp. stock logo
AKAN
Akanda
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akanda Corp. stock logo
AKAN
Akanda
$260K11.03N/AN/A($25.68) per share-0.21
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$10K314.74N/AN/A$2.04 per share0.33
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/AN/AN/AN/A$2.88 per shareN/A
PainReform Ltd. stock logo
PRFX
PainReform
$20K43.50N/AN/A$23.07 per share0.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akanda Corp. stock logo
AKAN
Akanda
-$45.65MN/AN/AN/AN/AN/AN/AN/AN/A
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$5.99M-$2.14N/AN/AN/AN/A-88.38%-84.71%8/14/2026 (Estimated)
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
-$10.31M-$0.91N/AN/AN/AN/A-35.32%-30.94%N/A
PainReform Ltd. stock logo
PRFX
PainReform
-$5.02M-$736.66N/AN/AN/AN/AN/AN/AN/A

Latest PRFX, CELZ, AKAN, and GLMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026N/A
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$0.39N/AN/AN/AN/AN/A
6/9/2026Q4 2025
Akanda Corp. stock logo
AKAN
Akanda
N/A-$317.9020N/A-$317.9020N/AN/A
5/8/2026Q1 2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$0.39-$0.38+$0.01-$0.38N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akanda Corp. stock logo
AKAN
Akanda
N/AN/AN/AN/AN/A
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
N/AN/AN/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/AN/AN/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akanda Corp. stock logo
AKAN
Akanda
N/A
0.58
0.58
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
N/A
19.67
19.67
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/A
7.71
7.71
PainReform Ltd. stock logo
PRFX
PainReform
N/A
1.78
1.78

Institutional Ownership

CompanyInstitutional Ownership
Akanda Corp. stock logo
AKAN
Akanda
1.00%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
1.42%
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
76.14%
PainReform Ltd. stock logo
PRFX
PainReform
37.28%

Insider Ownership

CompanyInsider Ownership
Akanda Corp. stock logo
AKAN
Akanda
20.39%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
1.00%
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
19.80%
PainReform Ltd. stock logo
PRFX
PainReform
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akanda Corp. stock logo
AKAN
Akanda
110540,000431,000Not Optionable
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
54.74 million4.69 millionNot Optionable
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
206.60 million4.39 millionNot Optionable
PainReform Ltd. stock logo
PRFX
PainReform
4870,000570,000Not Optionable

Recent News About These Companies

PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms
July 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/27/3333512/0/en/prf-technologies-issues-letter-to-shareholders-highlighting-strengthened-financial-position-and-building-momentum-across-its-biotechnology-and-ai-driven-energy-platforms.html
PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330457/0/en/prf-technologies-to-showcase-gridfeed-at-energy-trading-week-europe-2026.html
PRF Technologies Expands DeepSolar Predict™ Platform with Battery-to-Revenue Intelligence, Extending AI-Driven Revenue Optimization Across Solar and Energy Storage Assets
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327824/0/en/prf-technologies-expands-deepsolar-predict-platform-with-battery-to-revenue-intelligence-extending-ai-driven-revenue-optimization-across-solar-and-energy-storage-assets.html
PRF Technologies' DeepSolar Successfully Validates Predict™ AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324076/0/en/prf-technologies-deepsolar-successfully-validates-predict-ai-platform-for-renewable-energy-revenue-optimization-using-real-world-european-market-data.html
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark
June 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/25/3317531/0/en/prf-technologies-reports-expanded-preclinical-results-for-prf-110-in-head-to-head-comparison-with-approved-benchmark.html
PainReform Shareholders Approve All Proposals at Adjourned 2026 Annual Meeting
June 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PRFX/pressreleases/36936522/painreform-shareholders-approve-all-proposals-at-adjourned-2026-annual-meeting/
PRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3302841/0/en/prf-technologies-advances-deepsolar-predict-toward-commercial-launch-as-ai-platform-targets-revenue-optimization-across-renewable-energy-markets.html
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
May 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3301087/0/en/prf-technologies-announces-prf-110-demonstrated-sustained-72-hour-analgesic-activity-comparable-to-approved-commercially-available-benchmark-in-head-to-head-preclinical-study.html
PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282536/0/en/prf-technologies-announces-fda-clearance-of-ind-application-for-ocuring-k-phase-ii-clinical-trial.html
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms
March 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/27/3263728/0/en/prf-technologies-provides-year-end-2025-business-update-highlighting-strategic-progress-across-healthcare-and-ai-driven-solar-platforms.html
PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements
March 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/17/3257187/0/en/prf-technologies-ltd-announces-commercial-collaboration-agreement-with-blade-ranger-to-accelerate-large-scale-deepsolar-commercial-engagements.html
PRF Technologies’ DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy
February 18, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prf-technologies-deepsolar-announces-its-first-commercial-due-diligence-engagement-with-edf-power-solutions-israel-a-global-leader-in-renewable-energy-1035840319
PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy
February 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/18/3240327/0/en/prf-technologies-deepsolar-announces-its-first-commercial-due-diligence-engagement-with-edf-power-solutions-israel-a-global-leader-in-renewable-energy.html
PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base
February 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/11/3236284/0/en/prf-technologies-wins-another-european-utility-scale-solar-deployment-expanding-deepsolar-s-installed-commercial-base.html
PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy
January 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/20/3221829/0/en/prf-technologies-files-its-first-patent-application-for-solar-plant-micro-climate-forecast-modeling-designed-to-improve-energy-production-forecast-accuracy.html
PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push
January 16, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/01/49970381/painreform-stock-spikes-as-it-rebrands-expands-beyond-pharma-with-ai-clean-energy-push
PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push
January 16, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/01/49970381/painreform-stock-spikes-as-it-rebrands-expands-beyond-pharma-with-ai-clean-energy-push?utm_source=snapi
PainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy Platforms
January 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/painreform-ltd-changes-name-prf-210500625.html
PainReform Rebrands as PRF Technologies to Reflect Expansion into Healthcare and AI-Driven Energy
January 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/painreform-rebrands-as-prf-technologies-to-reflect-expansion-into-healthcare-and-ai-driven-energy?utm_source=marketbeat.com&utm_medium=referral
PainReform Ltd. Changes Name to PRF Technologies Ltd.
January 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/15/3219986/0/en/painreform-ltd-changes-name-to-prf-technologies-ltd-reflecting-expansion-into-diversified-healthcare-and-ai-driven-energy-platforms.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akanda stock logo

Akanda NASDAQ:AKAN

$5.31 -1.08 (-16.90%)
Closing price 04:00 PM Eastern
Extended Trading
$5.25 -0.06 (-1.13%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.

Creative Medical Technology stock logo

Creative Medical Technology NASDAQ:CELZ

$0.66 -0.10 (-13.12%)
Closing price 04:00 PM Eastern
Extended Trading
$0.67 +0.01 (+1.36%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Galmed Pharmaceuticals stock logo

Galmed Pharmaceuticals NASDAQ:GLMD

$0.62 +0.02 (+3.67%)
Closing price 04:00 PM Eastern
Extended Trading
$0.59 -0.03 (-4.51%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

PainReform stock logo

PainReform NASDAQ:PRFX

$1.00 -0.03 (-2.91%)
Closing price 04:00 PM Eastern
Extended Trading
$0.99 -0.01 (-1.30%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas